14.94
前日終値:
$15.92
開ける:
$16.24
24時間の取引高:
1.71M
Relative Volume:
1.24
時価総額:
$1.74B
収益:
$674.41M
当期純損益:
$-173.05M
株価収益率:
-9.7373
EPS:
-1.5343
ネットキャッシュフロー:
$-48.07M
1週間 パフォーマンス:
-5.68%
1か月 パフォーマンス:
-16.21%
6か月 パフォーマンス:
+41.61%
1年 パフォーマンス:
+6.33%
Novocure Ltd Stock (NVCR) Company Profile
Compare NVCR vs ABT, MDT, SYK, BSX, EW
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
|
NVCR
Novocure Ltd
|
14.94 | 1.84B | 674.41M | -173.05M | -48.07M | -1.5343 |
|
ABT
Abbott Laboratories
|
97.50 | 175.27B | 46.59B | 5.41B | 7.38B | 3.0938 |
|
MDT
Medtronic Plc
|
86.38 | 113.38B | 36.36B | 4.84B | 5.43B | 3.7261 |
|
SYK
Stryker Corp
|
275.43 | 104.47B | 25.27B | 3.34B | 4.57B | 8.6334 |
|
BSX
Boston Scientific Corp
|
42.60 | 63.65B | 20.62B | 3.56B | 3.48B | 2.3847 |
|
EW
Edwards Lifesciences Corp
|
85.15 | 49.74B | 6.30B | 1.07B | 1.09B | 1.8406 |
Novocure Ltd Stock (NVCR) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-07-25 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2025-07-08 | 開始されました | Ladenburg Thalmann | Buy |
| 2024-12-02 | アップグレード | Evercore ISI | In-line → Outperform |
| 2024-10-16 | アップグレード | H.C. Wainwright | Neutral → Buy |
| 2023-11-20 | 再開されました | JP Morgan | Neutral |
| 2023-08-28 | ダウングレード | H.C. Wainwright | Buy → Neutral |
| 2023-08-08 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2023-08-04 | 開始されました | SVB Securities | Outperform |
| 2023-07-31 | アップグレード | Evercore ISI | Underperform → In-line |
| 2023-06-07 | アップグレード | Wedbush | Underperform → Neutral |
| 2023-05-16 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2023-03-17 | ダウングレード | JP Morgan | Neutral → Underweight |
| 2023-01-06 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2023-01-05 | 繰り返されました | H.C. Wainwright | Buy |
| 2022-11-29 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2022-10-24 | ダウングレード | Piper Sandler | Overweight → Neutral |
| 2022-07-05 | ダウングレード | Evercore ISI | In-line → Underperform |
| 2022-05-16 | 開始されました | H.C. Wainwright | Buy |
| 2022-02-08 | 開始されました | Loop Capital | Buy |
| 2022-02-02 | アップグレード | Oppenheimer | Perform → Outperform |
| 2022-01-20 | アップグレード | Truist | Hold → Buy |
| 2022-01-03 | アップグレード | Evercore ISI | Underperform → In-line |
| 2021-07-01 | ダウングレード | Mizuho | Buy → Neutral |
| 2021-04-14 | ダウングレード | Wedbush | Neutral → Underperform |
| 2021-01-25 | 繰り返されました | Piper Sandler | Overweight |
| 2020-09-23 | 開始されました | Northland Capital | Outperform |
| 2020-09-18 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2020-09-17 | ダウングレード | Truist | Buy → Hold |
| 2020-06-01 | 再開されました | Oppenheimer | Perform |
| 2020-05-01 | ダウングレード | Oppenheimer | Outperform → Perform |
| 2020-04-09 | ダウングレード | Evercore ISI | In-line → Underperform |
| 2020-03-05 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2020-01-02 | ダウングレード | Evercore ISI | Outperform → In-line |
| 2019-07-29 | アップグレード | SunTrust | Hold → Buy |
| 2019-07-26 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2019-07-26 | ダウングレード | Wedbush | Outperform → Neutral |
| 2019-03-20 | 開始されました | SunTrust | Hold |
| 2018-11-02 | ダウングレード | Wells Fargo | Outperform → Market Perform |
| 2018-07-16 | 開始されました | Evercore ISI | Outperform |
| 2018-04-18 | 繰り返されました | Mizuho | Buy |
| 2018-02-23 | 繰り返されました | Mizuho | Buy |
| 2017-05-24 | アップグレード | Wells Fargo | Market Perform → Outperform |
| 2016-07-29 | 繰り返されました | Wedbush | Outperform |
| 2016-01-19 | 開始されました | Barclays | Underweight |
| 2015-12-02 | 開始されました | Deutsche Bank | Hold |
すべてを表示
Novocure Ltd (NVCR) 最新ニュース
Novocure Receives Approval In Japan For Optune Pax For The Treatment Of Unresectable Locally Advanced Pancreatic Cancer - marketscreener.com
Japan approves a wearable device to use with chemo for advanced pancreatic cancer. - Stock Titan
A results call is set for 8 a.m. Oct. 29, when Novocure will discuss third-quarter results. - Stock Titan
Price to earnings forward of NovoCure Ltd. – HAN:038 - TradingView
ETFs Investing in NovoCure Ltd. Stocks - TradingView
Tariff Cuts Put NovoCure Stock And Medical Exporters Back In Focus - Simply Wall Street
Novocure Stock Price Forecast. Should You Buy NVCR? - StockInvest.us
NovoCure stock reports 15.6 percent Q2 revenue growth - AD HOC NEWS
NovoCure Limited (NVCR) Stock Price, News, Quote & History - Yahoo! Finance Canada
Is NovoCure (NVCR) Undervalued On TTFields Validation And Board Change? - simplywall.st
NovoCure (NVCR) Stock Still Looks Cheap After Its 86% Fall - Yahoo Finance Singapore
NovoCure (NVCR) Could Be 36% Undervalued Despite Its Recent Board Change - Yahoo Finance Singapore
Growth Plan Might Change The Case For Investing In NovoCure Stock (NVCR) - simplywall.st
NovoCure Eyes Glioblastoma Growth, Cancer Launches and EBITDA Break-Even - TradingView
Is It Too Late to Buy NovoCure Ltd (NVCR) After 3.1% Rally? GF V - GuruFocus
Novocure at Morgan Stanley conference: growth, discipline and expansion By Investing.com - Investing.com India
NovoCure Limited at Morgan Stanley Global Healthcare Conference Transcript - GuruFocus
Novocure at Morgan Stanley conference: growth, discipline and expansion - Investing.com
NovoCure (NVCR) Stock Looks Cheap On Sales But Weak On Adoption Risk - simplywall.st
NovoCure (NASDAQ: NVCR) Announces Board Vacancy Following Timothy Scannell's Departure on September 2, 2026 - kalkinemedia.com
NovoCure at Wells Fargo healthcare conference: launch momentum builds By Investing.com - Investing.com South Africa
NovoCure at Wells Fargo healthcare conference: launch momentum builds - Investing.com
Novocure Ltd Announces Retirement of Timothy Scannell from the Board, Effective September 2, 2026 - marketscreener.com
Timothy Scannell retires from NovoCure board, seat vacated Sept 2, 2026 - TradingView
NovoCure (NASDAQ: NVCR) director steps down with no dispute - Stock Titan
Novocure Reports Patient Data Exposure in Cybersecurity Incident - Yahoo Finance
NOVOCURE LTD (NVCR) Stock Chart - ChartMill
Novocure Ltd (NVCR) Key Financial Ratios – Valuation, Profitability & More - Value Research
Cash flow from operating activities of NovoCure Ltd. – HAM:038 - TradingView
Net debt of NovoCure Ltd. – HAM:038 - TradingView
NovoCure says cyberattack caused patient data exposure - Yahoo Finance
Basic earnings per share (basic EPS) of NovoCure Ltd. – HAM:038 - TradingView
NovoCure (NVCR) Stock May Be Cheap Based On Sales Growth Risk - simplywall.st
NewsNovocure discloses cyberattack exposing records of more than 1,400 US cancer patients - teiss
Novocure Announces Upcoming Investor Events - finance.yahoo.com
NovoCure (NASDAQ: NVCR) Data Breach Exposes IDs Linked to Over 1,400 U.S. Patient Records - Kalkine Media
Novocure Reveals Major Breach of Cancer Patient Records - sqmagazine.co.uk
Oncology firm Novocure says cyberattack exposed US patient records - CNA
NVCR Looks 3.4% Undervalued on GF Value™ Amid Cybersecurity Inci - GuruFocus
Novocure reports data access affecting patient IDs for 1,400+ U.S. records; no device access - TradingView
NovoCure cyber breach hits 1,400+ patient records - Stock Titan
Novocure Ltd (NVCR) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
Novocure Ltd (NVCR) Peer Comparison – Compare with Others - Value Research
Is NovoCure (NVCR) A Bargain On Rising Earnings Estimates? - simplywall.st
NovoCure Limited (NVCR) Stock Price & News - Syfe
Wall Street Analysts See a 50.86% Upside in NovoCure (NVCR): Can the Stock Really Move This High? - Yahoo Finance
Should NovoCure’s (NVCR) Upgraded Momentum Score and Earnings Revisions Require Action From Investors? - simplywall.st
A Look at NovoCure Ltd (NVCR) After 3.7% Decline -- GF Value $18 - GuruFocus
NovoCure (NASDAQ:NVCR) Shares Down 4%What's Next? - MarketBeat
Are You Looking for a Top Momentum Pick? Why NovoCure (NVCR) is a Great Choice - Yahoo Finance
Novocure | 8-K: Current report - Moomoo
Novocure Ltd (NVCR) 財務データ
収益
当期純利益
現金流量
EPS
Novocure Ltd (NVCR) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Leonard Frank X | Chief Executive Officer |
Jun 04 '26 |
Sale |
17.93 |
34,273 |
614,635 |
459,520 |
大文字化:
|
ボリューム (24 時間):